On 17 November 2025, Sandoz announced the US launch of Tyruko®, biosimilar to Biogen’s Tysabri® (natalizumab). Tyruko® is the only natalizumab biosimilar approved (August 2023) and launched in the US and is available for all reference indications.
Tyruko® was developed by Polpharma Biologics pursuant to a global commercialisation agreement with Sandoz reached in 2019. As part of the agreement, Sandoz has exclusive rights to commercialise and distribute the product in all markets.
Tyruko® was approved in Europe (September 2023) and Australia (April 2025) and was recommended for listing on Australia’s Pharmaceutical Benefits Scheme (PBS) under the same circumstances as Biogen’s Tysabri® in April 2025.